业绩经营情况 公司预计2026年营收为7.96亿至8.29亿元，同比增长49.45%至55.55%，主要受益于重组人凝血酶医保放 量及吉卡西替尼商业化推进。 泽璟制药与艾伯维就ZG006药物达成全球开发及商业化协议，艾伯维获得大中华区以外独家权利；泽璟 已收到1亿美元首付款，并可能获得最高6000万美元近期里程碑付款及10.75亿美元远期里程碑付款。 ZG006针对小细胞肺癌和神经内分泌癌的临床试验数据显示，在II期剂量优化试验中，10mg组确认客观 缓解率（ORR）达53.3%，中位无进展生存期（mPFS）为7.03个月。 产品研发进展 除ZG006外，注射用ZG005在宫颈癌II期临床试验中确认ORR为40.9%，疾病控制率（DCR）68.2%；公 司多款候选药物如ZGGS18、ZGGS34等已进入中美I期临床阶段。 经济观察网 根据截至2026年2月14日的公开信息，泽璟制药-U（688266.SH）近期有以下事件值得关 注： 高管减持 公司公告称，股东ZELIN SHENG（盛泽林）拟减持不超过273,907股（占总股本0.1035%），股东宁波 泽奥拟减持不超过2,475,090股（占总股本0.93 ...

2026年2月13日，泽璟制药披露接待调研公告，公司于2月2日至2月10日接待淡水泉、农银汇理、安信基 金、华安基金、建信资产、平安基金等28家机构调研。 调研情况显示，泽璟制药与艾伯维就ZG006达成全球开发及商业化战略合作与许可选择权协议，艾伯维 获大中华区以外地区独家权利，泽璟保留区内权利；泽璟已收到1亿美元首付款，还可获最高6000万美 元近期里程碑及许可选择付款，若选择权行使另有最高10．75亿美元里程碑付款和高个位数到中双位数 阶梯特许权使用费。ZG006正推进单药及联合用药治疗小细胞肺癌、神经内分泌癌等临床试验，包括关 键及III期试验；在晚期小细胞肺癌三线及以上II期剂量优化试验中，10mg每两周一次组确认ORR为53． 3％、mPFS达7．03个月，6个月及12个月OS率分别为83．2％及69．1％；治疗神经内分泌癌推荐剂量 组全人群确认ORR38．5％，DLL3阳性患者达66．7％。 注射用ZG005正推进单药及联合用药治疗肝癌、神经内分泌癌、宫颈癌等试验；二线及以上宫颈癌 20mg／kg Q3W方案确认ORR40．9％、DCR68．2％、mPFS超11个月，联合方案一线宫颈癌及早期肝 癌 ...

Core Viewpoint - Suzhou Zelgen Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of injectable ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal carcinoma and esophageal squamous cell carcinoma [2] Group 1: Drug Information - Injectable ZG005 is a recombinant humanized dual-specificity antibody targeting PD-1 and TIGIT, classified as a Class 1 innovative tumor immunotherapy biological product, with potential applications for various solid tumors [3] - ZG005 is one of the first drugs globally to enter clinical research targeting the same mechanism, with no similar mechanism drugs approved for market worldwide [3] - The drug works by blocking both PD-1 and TIGIT pathways, enhancing T cell and NK cell activation and proliferation, thereby improving the immune system's ability to kill tumor cells [3] Group 2: Clinical Trial Approval Impact - The approval of the clinical trial for ZG005 in combination with platinum-based chemotherapy is not expected to have a significant impact on the company's recent performance [2] - The drug development process is lengthy and complex, involving high costs and multiple approval stages, which are subject to various uncertainties [2]

Core Viewpoint - Zai Lab (688266.SH) has received approval from the National Medical Products Administration for clinical trials of ZG005, a novel dual-specific antibody targeting PD-1 and TIGIT, for use in advanced nasopharyngeal carcinoma and esophageal squamous cell carcinoma [1] Group 1: Product Information - ZG005 is a recombinant humanized anti-PD-1/TIGIT dual-specific antibody classified as a Class 1 innovative tumor immunotherapy biological product [1] - ZG005 is among the first in the world to enter clinical research for this target mechanism, with no similar mechanism drugs approved globally [1] Group 2: Mechanism of Action - ZG005 simultaneously blocks PD-1 and TIGIT pathways, enhancing T cell activation and proliferation by inhibiting PD-1 signaling through its ligand PD-L1 [1] - The drug also effectively blocks the TIGIT pathway, promoting co-stimulatory activation signals through PVR and CD226, leading to increased activation and proliferation of T cells and NK cells [1] - The dual-target blockade is expected to synergistically enhance the immune system's ability to kill tumor cells [1]

人民财讯1月22日电，泽璟制药(688266)1月22日公告，公司于近日收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，注射用ZG005与含铂化疗联合用于晚期鼻咽癌和食管鳞癌的临床试验获 得批准。 ...

Policy Developments - Hunan Province has issued an implementation plan to promote provincial-level coordination of basic medical insurance, aiming to enhance the level of medical security and the fund's risk resistance by 2029 [2] Drug and Device Approvals - Zai Lab has received approval for clinical trials of injectable ZGGS18 and ZG005 for use in advanced solid tumors, although this will not significantly impact the company's recent performance [4] - Jianfeng Group has voluntarily withdrawn its clinical trial application for "C2235 and C2235 tablets," with plans to resubmit after further research [5] Capital Markets - WuXi AppTec has made a conditional cash acquisition offer of HKD 4.00 per share for all shares of Dongyao Pharmaceutical, representing a premium of approximately 114.67% over the average closing price for the last 30 trading days [7] - Yinuo Micro Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [8] Industry Events - Over 11,000 designated medical institutions are equipped to purchase 105 new drugs added to the medical insurance catalog for 2025, with 6,537 being medical institutions and 4,592 retail pharmacies [10][11] - France has launched a roadmap to address national obesity issues, setting four key objectives to curb obesity growth and improve health outcomes [12] Public Opinion Alerts - Sunflower has been investigated by the China Securities Regulatory Commission for misleading statements in its restructuring plan, leading to a 20% drop in its stock price [14]

Policy Developments - Hunan Province has issued an implementation plan to promote provincial-level coordination of basic medical insurance, aiming to enhance the level of medical security and fund risk resistance by 2029 [1] Drug and Device Approvals - Zai Lab has received clinical trial approval for injectable ZGGS18 and ZG005 for use in advanced solid tumors, although this will not significantly impact the company's recent performance [2] - Jianfeng Group has voluntarily withdrawn its clinical trial application for "C2235 and C2235 tablets," with plans to resubmit after further research [3] Capital Markets - WuXi AppTec has made a conditional cash acquisition offer of HKD 4.00 per share for all shares of Dongyao Pharmaceutical, representing a premium of approximately 114.67% over the average closing price for the previous 30 trading days [4] - Yinuo Micro Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [5] Industry Developments - Over 11,000 designated medical institutions are equipped to purchase 105 new drugs added to the 2025 medical insurance catalog, with 6,537 being medical institutions and 4,592 retail pharmacies [6][7] - France has launched a roadmap for addressing national obesity issues, with goals to curb obesity growth, improve health conditions, enhance accessibility to personalized medical services, and support innovative care methods from 2026 to 2030 [8] Public Opinion Alerts - Sunflower has been investigated by the China Securities Regulatory Commission for alleged misleading statements in its restructuring plan, leading to a 20% drop in its stock price [9]

Group 1 - The core point of the article is that Zai Lab (stock code: 688266) has received approval from the National Medical Products Administration for clinical trials of its drugs ZGGS18 and ZG005 in combination with chemotherapy for advanced solid tumors [1] Group 2 - The approved clinical trial will focus on the use of ZGGS18 and ZG005 in treating patients with advanced solid tumors [1] - This approval marks a significant step for the company in advancing its oncology pipeline [1] - The combination therapy aims to enhance treatment efficacy for patients suffering from late-stage cancer [1]

Core Viewpoint - Zai Jian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its innovative biopharmaceuticals ZGGS18 and ZG005 in combination with chemotherapy for advanced solid tumors [1][2] Group 1: ZGGS18 - ZGGS18 is a recombinant humanized anti-VEGF/TGF-β bifunctional antibody fusion protein classified as a Class 1 therapeutic biological product, expected to be an innovative treatment for solid tumors [1] - ZGGS18 specifically binds to vascular endothelial growth factor (VEGF) and captures transforming growth factor-β (TGF-β), inhibiting tumor angiogenesis and reducing metastasis, thereby exerting multiple synergistic effects on tumor growth suppression [1] - ZGGS18 can also improve and regulate the tumor microenvironment, enhancing the efficacy of tumor immunotherapy drugs such as anti-PD-1/L1 antibodies and the dual-specific antibody ZG005 currently undergoing clinical research [1] Group 2: ZG005 - ZG005 is a recombinant humanized dual-specific antibody targeting PD-1 and TIGIT, classified as a Class 1 innovative tumor immunotherapy biological product, with potential applications in treating various solid tumors [2] - ZG005 is one of the first drugs globally to enter clinical research targeting the same mechanism, with no similar mechanism drugs approved for market worldwide [2] - ZG005 effectively blocks both PD-1 and TIGIT signaling pathways, promoting T cell activation and proliferation, and enhancing the immune system's ability to kill tumor cells through simultaneous blockade of both targets [2]

Group 1 - The company has received approval from the National Medical Products Administration for the clinical trial of ZGGS18 and ZG005 in combination with chemotherapy for advanced solid tumors [1]